Multicenter retrospective study of intratumoral talimogene laherparepvec as salvage therapy for metastatic Merkel cell carcinoma

Only approximately 50% of patients with metastatic Merkel cell carcinoma (MCC) respond to immune checkpoint inhibitor (ICI) therapy, necessitating alternative salvage options. Talimogene laherparepvec (T-VEC) is and oncolytic herpes simplex virus approved for metastatic melanoma, but data on its use in MCC remain limited. A multicenter retrospective study evaluated eight patients with MCC who progressed on prior systemic therapy and were subequently treated with T-VEC between 2017 and 2024. Of the eight patients, seven were evaluable for response. Four of seven patients (57%) achieved objective response (OR) in injected lesions: one complete response and three partial responses, with a median time to OR of 9 months (range 1.2-14.2). Two of these four responders did not have any non-injected lesions, and therefore were classified as having an OR across all assessable lesions (median time to OR: 11 months;; range 7.8-14.2), with lasting responses after therapy completion at the last follow-up (range 0.9-5.1 years). The remaining two responders possessed non-injected disease that remained stable or progressed, with no lesions regressing without addition intervention, indicating a lack of clinically evident abscopal effect. Additionally, one of these patients developed additional distant metastases over their T-VEC treatment course. Two patients who achieved initial CR received repeat T-VEC courses, with one progression on the final course. Grade 3 adverse events occurred in two of eight patients. The authors conclude that T-VEC is a minimally toxic salvage option that provided meaningful clinical benefit in four of eight evaluable patients with ICI-refractory MCC.